Skip to main content
SpringerLink
Log in
Book cover

Cancer Chemoprevention pp 3–37Cite as

Characterization of Natural Product Chemopreventive Agents

  • Chapter

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Cancer is a complicated group of diseases characterized by the uncontrolled growth and spread of abnormal cells (1). In 2002, 1,284,900 new cases of cancer were estimated to be diagnosed in the United States (US), and about 555,500 persons were expected to die of cancer, i.e., more than 1500 every day (2). Despite small decreases in overall cancer incidence and mortality rates in the US since the early 1990s, the total number of recorded cancer deaths continues to increase due to an aging and expanding population (2). Furthermore, deaths from certain carcinomas of the lung and bronchus, breast, prostate, and colon and rectum remain high, and 5-yr survival rates for many cancer patients are still very low: for cancers of the brain, 32%; esophagus, 14%; liver, 6%; lung and bronchus, 15%; pancreas, 4%; stomach, 22%; and multiple myeloma, 29% (2). Obviously, cancer remains a formidable public health problem.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. The Anticancer Drugs. Oxford University Press, Oxford, 1994.

    Google Scholar 

  2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52: 23–47.

    PubMed  Google Scholar 

  3. Sporn MB. The war on cancer. Lancet 1996;347:1377–1381.

    Article  PubMed  CAS  Google Scholar 

  4. Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 1997;53:121–133.

    Article  PubMed  CAS  Google Scholar 

  5. Alberts DS, Colvin GM, Conney AH, et al. Prevention of cancer in the next millennium. Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999;59: 4743–4758.

    Google Scholar 

  6. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525–530.

    Article  PubMed  CAS  Google Scholar 

  7. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332–1338.

    PubMed  CAS  Google Scholar 

  8. Wattenberg L. Chemoprevention of cancer. Cancer Res 1985;45:1–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kelloff GJ, Boone CW, Steele VE, et al. Inhibition of chemical carcinogens. In Chemical Induction of Cancer. Arcos JC, ed. Birkauser, Basel, 1995; pp.73–122.

    Google Scholar 

  10. Surh YJ. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999;428:305–327.

    PubMed  CAS  Google Scholar 

  11. Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999;35:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  12. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991;51(Suppl): 5023S–5044S.

    PubMed  CAS  Google Scholar 

  13. Greenwald P, Kelloff GJ, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer J Clin 1995; 45:31–49.

    Article  PubMed  CAS  Google Scholar 

  14. Stoner GD, Morse MA, Kelloff GJ. Perspectives in cancer chemoprevention. Environ Health Perspect 1997;105(Suppl):945–954.

    Article  PubMed  CAS  Google Scholar 

  15. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990;50:2–9.

    PubMed  CAS  Google Scholar 

  16. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993;4: 1737–1746.

    Article  Google Scholar 

  17. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 1999;78: 199–334.

    Article  Google Scholar 

  18. Mirvish SS. Ascorbic acid inhibition of N-nitroso compound formation in chemical, food, and biological systems. In Inhibition of Tumor Induction and Development. Zedeck MS, Lipkin M, eds. Plenum New York, 1981; pp. 101–126.

    Google Scholar 

  19. Kuenzig W, Chau J, Norkus E, et al. Caffeic and ferulic acid as blockers of nitrosamine formation. Carcinogenesis 1984;5: 309–313.

    Article  PubMed  CAS  Google Scholar 

  20. Shenoy NR, Choughuley ASU. Inhibitory effect of diet related sulphydryl compounds on the formation of carcinogenic nitrosamines. Cancer Lett 1992;65:227–232.

    Article  PubMed  CAS  Google Scholar 

  21. Wakabayashi K, Nagao M, Sugimura T. Prevention of formation of carcinogens in food. Heterocyclic amines, lipophilic ascorbic acid, and thioproline: ubiquitous carcinogens and practical anticarcinogenic substances. In Cancer Chemoprevention. Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds. CRC Press, Boca Raton, 1992; pp. 311–325.

    Google Scholar 

  22. Kelloff GJ, Hawk ET, Karp JE, et al. Progress in clinical chemoprevention. Semin Oncol 1997; 24:241–252.

    PubMed  CAS  Google Scholar 

  23. Kelloff GJ, Crowell JA, Hawk ET, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem 1996;26(Suppl):54–71.

    Article  CAS  Google Scholar 

  24. Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention. Ann NY Acad Sci 1999;889:1–13.

    Article  PubMed  CAS  Google Scholar 

  25. Kelloff GJ, Boone CW, Malone WF, Steele VE. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In Cancer Chemoprevention. Wattenberg L, Lipkin M, Boone CW, eds. CRC Press, Boca Raton, 1992; pp. 41–56.

    Google Scholar 

  26. Kelloff GJ, Boone CW, Crowell JA, et al. New agents for cancer chemoprevention. J Cell Biochem 1996;26(Suppl): 1–28.

    CAS  Google Scholar 

  27. Udeani GO, Zhao GM, Shin YG, et al. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer Chemother Pharmacol 2001;47:263–268.

    Article  PubMed  CAS  Google Scholar 

  28. Kelloff GJ, Johnson JR, Crowell JA, et al. Approaches to development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1–10.

    PubMed  CAS  Google Scholar 

  29. Pezzuto JM. Cancer chemopreventive agents: from plant materials to clinical intervention trials. In Human Medicinal Agents from Plants (Symposium Series No. 534). Kinghorn AD, Balandrin MF, eds. American Chemical Society Books, Washington, DC, 1993; pp. 205–217.

    Google Scholar 

  30. Pezzuto JM. Natural product cancer chemopreventive agents. In Recent Advances in Phytochemistry (Vol. 29): Phytochemistry of Medicinal Plants. Arnason JT, Mata R, Romeo JT, eds. Plenum, New York, 1995; pp. 19–44.

    Google Scholar 

  31. Kinghorn AD, Fong HHS, Farnsworth NR, et al. Cancer chemopreventive agents discovered by activity-guided fractionation: a review. Curr Org Chem 1998;2:597–612.

    CAS  Google Scholar 

  32. Pezzuto JM, Angerhofer CK, Mehdi H. In vitro models of human disease states. Stud Nat Prod Chem 1998;20:507–560.

    Article  CAS  Google Scholar 

  33. Pezzuto JM, Song LL, Lee SK, et al. Bioassay methods useful for activity-guided isolation of natural product cancer chemopreventive agents. In Chemistry, Biological and Pharmacological Properties of Medicinal Plants from the Americas. Hostettmann K, Gupta MP, Marston A, eds. Harwood Academic Publishers, Chur, Switzerland, 1998; pp. 81–110.

    Google Scholar 

  34. Mehta RG, Moon RC. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res 1991;11:593–596.

    PubMed  CAS  Google Scholar 

  35. Mehta RG, Bhat KPL, Hawthorne ME, et al. Induction of atypical ductal hyperplasia in mouse mammary gland organ culture. J Natl Cancer Inst 2001;93:1103–1106.

    Article  PubMed  CAS  Google Scholar 

  36. Loub WD, Farnsworth NR, Soejarto DD, Quinn ML. NAPRALERT: computer handling of natural product research data. J Chem Inf Comput Sci 1985;25:99–103.

    PubMed  CAS  Google Scholar 

  37. Shamon LA, Pezzuto JM. Assessment of antimutagenic activity with Salmonella typhimurium strain TM677. Methods Cell Sci 1997;19:57–62.

    Article  Google Scholar 

  38. Chung HS, Chang LC, Lee SK, et al. Flavonoid constituents of Chorizanthe diffusa with potential cancer chemopreventive activity. J Agric Food Chem 1999;47:36–41.

    Article  PubMed  CAS  Google Scholar 

  39. Lee SK, Mbwambo ZH, Chung H-S, et al. Evaluation of the antioxidant potential of natural products. Comb Chem High Throughput Screen 1998;1:23–34.

    Google Scholar 

  40. Song LL, Kosmeder JW II, Lee SK, et al. Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res 1999;59: 578–585.

    PubMed  CAS  Google Scholar 

  41. Chang LC, Chávez D, Song LL, et al. Absolute configuration of novel bioactive flavonoids from Tephrosia purpurea. Org Lett 2000;2:515–518.

    Article  PubMed  CAS  Google Scholar 

  42. Gerhäuser C, Lee SK, Kosmeder J, et al. Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res 1997;57:3429–3435.

    PubMed  Google Scholar 

  43. Chang LC, Song LL, Park EJ, et al. Bioactive constituents of Thuja occidentalis. J Nat Prod 2000;63;1235–1238.

    Article  PubMed  CAS  Google Scholar 

  44. Jang M, Pezzuto JM. Assessment of cyclooxygenase inhibitors using in vitro assay systems. Methods Cell Sci 1997;19:25–31.

    Article  Google Scholar 

  45. Waffo-Teguo P, Lee D, Cuendet M, et al. Two new stilbene dimer glucosides from grape (Vitis vinifera) cell cultures. J Nat Prod 2001;64:136–138.

    Article  PubMed  CAS  Google Scholar 

  46. Lee D, Cuendet M, Schunke Vigo J, et al. A novel cyclooxygenase-inhibitory stilbenolignan from the seeds of Aiphanes aculeata. Org Lett 2001;3:2169–2171.

    Article  PubMed  CAS  Google Scholar 

  47. Mbwambo ZH, Lee SK, Mshiu EN, et al. Constituents from the stem wood of Euphorbia quinquecostata with phorbol dibutyrate receptor-binding inhibitory activity. J Nat Prod 1996;59:1051–1055.

    Article  PubMed  CAS  Google Scholar 

  48. El-Sayed KA, Hamann MT, Waddling CA, et al. Structurally novel bioconversion products of the marine natural product sarcophine effectively inhibit JB6 cell transformation. J Org Chem 1998;63:7449–7455.

    Article  PubMed  CAS  Google Scholar 

  49. Mata-Greenwood E, Ito A, Westenburg H, et al. Discovery of novel inducers of cellular differentiation using HL-60 promyelocytic cells. Anticancer Res 2001;21:1763–1770.

    PubMed  CAS  Google Scholar 

  50. Mata-Greenwood E, Daeuble JF, Grieco PA, et al. Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture. J Nat Prod 2001;64:1509–1513.

    Article  PubMed  CAS  Google Scholar 

  51. Jeong H-J, Shin YG, Kim IH, Pezzuto JM. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 1999;22: 309–312.

    PubMed  CAS  Google Scholar 

  52. Pisha E, Pezzuto JM. Cell-based assay for the determination of estrogenic and anti-estrogenic activity. Methods Cell Sci 1997;19:37–43.

    Article  Google Scholar 

  53. Chang LC, Gills JJ, Bhat KPL, et al. Activity-guided isolation of constituents of Cerbera manghas with antiproliferative and antiestrogenic activities. Bioorg Med Chem Lett 2000;10: 2431–2434.

    Article  PubMed  CAS  Google Scholar 

  54. Chang LC, Bhat KPL, Fong HHS, et al. Novel bioactive steroidal alkaloids from Pachysandra procumbens. Tetrahedron 2000;56:3133–3138.

    Article  CAS  Google Scholar 

  55. Chang LC, Chávez D, Gills JJ, et al. Rubiasins A-C, new anthracene derivatives from the roots and stems of Rubia cordifolia. Tetrahedron Lett 2000;41:7157–7162.

    Article  CAS  Google Scholar 

  56. Su B-N, Park EJ, Mbwambo ZH, et al. New chemical constituents of Euphorbia quinquecostata and absolute configuration assignment by a convenient Mosher ester procedure carried out in NMR tubes. J Nat Prod 2002; 65:1278–1282.

    Article  PubMed  CAS  Google Scholar 

  57. Su B-N, Chang LC, Park EJ, et al. Bioactive constituents of the seeds of Brucea javanica. Planta Med 2002;68:730–733.

    CAS  Google Scholar 

  58. Constant HL, Slowing K, Graham JG, et al. A general method for the dereplication of flavonoid glycosides utilising HPLC/MS analysis. Phytochem Anal 1997;8:176–180.

    Article  CAS  Google Scholar 

  59. Gu J-Q, Park EJ, Luyengi L, et al. Constituents of Eugenia sandwicensis with potential cancer chemopreventive activity. Phytochemistry 2001;58:121–127.

    Article  PubMed  CAS  Google Scholar 

  60. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218–220.

    Article  PubMed  CAS  Google Scholar 

  61. Udeani GO, Gerhäuser C, Thomas CF, et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 1997;57:3424–3428.

    PubMed  CAS  Google Scholar 

  62. Prochaska HJ, Talalay P. Role of NAD(P)H:quinone reductase in protection against the toxicities of quinones and related agents. In Oxidative Stress. Oxidants and Antioxidants. Sies H., ed. Academic Press, London, 1991; pp. 195–211.

    Google Scholar 

  63. Yang CS, Smith TJ, Hong JY. Cytochrome P-450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity: opportunities and limitations. Cancer Res 1994;54:1982s–1986s.

    PubMed  CAS  Google Scholar 

  64. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002;99: 11908–11913.

    Article  PubMed  CAS  Google Scholar 

  65. Sogawa K, Fujii-Kuriyama Y. Ah receptor, a novel ligandactivated transcription factor. J Biochem (Tokyo) 1997;122: 1075–1079.

    CAS  Google Scholar 

  66. Talalay P. Chemical protection against cancer by induction of electrophile detoxication (Phase 2) enzymes. In Cellular Targets for Chemoprevention. Steele V, ed. Boca CRC Press, Raton, 1992; pp. 193–205.

    Google Scholar 

  67. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988;169:328–336.

    Article  PubMed  CAS  Google Scholar 

  68. De Long MJ, Santamaria AB, Talalay P. Role of cytochrome P1-450 in the induction of NAD(P)H:quinone reductase in a murine hepatoma cell line and its mutants. Carcinogenesis 1987;8:1549–1553.

    Article  PubMed  Google Scholar 

  69. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996; 96:1027–1039.

    Article  PubMed  CAS  Google Scholar 

  70. Lee SK, Song L, Mata-Greenwood E, et al. Modulation of in vitro biomarkers of the carcinogenic process by chemopreventive agents. Anticancer Res 1999;19:35–44.

    PubMed  CAS  Google Scholar 

  71. Ray AB, Gupta M. Withasteroids, a growing group of naturally occurring steroidal lactones. Fortschr Chem Org Naturst 1994;63:1–106.

    PubMed  CAS  Google Scholar 

  72. Kennelly EJ, Gerhäuser C, Song LL, et al. Induction of quinone reductase by withanolides isolated from Physallis philadelphica (tomatillos). J Agric Food Chem 1997;45: 3771–3777.

    Article  CAS  Google Scholar 

  73. Misico RI, Song LL, Veleiro AS, et al. Induction of quinone reductase by withanolides. J Nat Prod 2002;65:677–680.

    Article  PubMed  CAS  Google Scholar 

  74. Chang LC, Gerhäuser C, Song L, et al. Activity-guided isolation of constituents of Tephrosia purpurea with the potential to induce the phase 2 enzyme, quinone reductase. J Nat Prod 1997;60:869–873.

    Article  PubMed  CAS  Google Scholar 

  75. Mehta RG, Liu J, Constantinou A, et al. Structure-activity relationships of brassinin in preventing the development of carcinogen-induced mammary lesions in organ culture. Anticancer Res 1994;14: 1209–1213.

    PubMed  CAS  Google Scholar 

  76. Mehta RG, Liu J, Constantinou A, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995;16:399–404.

    Article  PubMed  CAS  Google Scholar 

  77. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 1992;89:2399–2403.

    Article  PubMed  CAS  Google Scholar 

  78. Gerhäuser C, You M, Liu J, et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res 1997;57:272–278.

    PubMed  Google Scholar 

  79. Kosmeder JW, Song, LS Park, EJ et al. Cancer chemopreventive activity of oxomate, a monofunctional inducer of phase 2 detoxification enzymes. Abstracts of Papers, 224th National Meeting of the American Chemical Society, Boston, MA, August 18-22, 2002; American Chemical Society: Washington, DC; MEDI 98.

    Google Scholar 

  80. Pezzuto JM, Park EJ. Autoxidation and antioxidants. In Encyclopedia of Pharmaceutical Technology, 2nd ed., vol. 1. Swarbrick J, Boylan JC, eds. Marcel Dekker, New York, 2002; pp. 97–113.

    Google Scholar 

  81. Gromadzinska J, Wasowicz W. The role of reactive oxygen species in the development of malignancies. Int J Occup Med Environ Health 2000;13:233–245.

    PubMed  CAS  Google Scholar 

  82. Kensler TW, Egner PA, Taffe BG, Trush MA. Role of free radicals in tumor promotion and progression. Prog Clin Biol Res 1989;298:233–248.

    PubMed  CAS  Google Scholar 

  83. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 1993;69: 261–274.

    PubMed  CAS  Google Scholar 

  84. Afaq F, Adhami VM, Ahmad N, Mukhtar H. Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci 2002;7:d784–792.

    Article  Google Scholar 

  85. Schlesier K, Harwat M, Bohm V, Bitsch R. Assessment of antioxidant activity by using different in vitro methods. Free Radic Res 2002;36:177–187.

    Article  PubMed  CAS  Google Scholar 

  86. Newburger PE, Chovaniec ME, Greenberger JS, Cohen HJ. Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 1979;82:315–322.

    Article  PubMed  CAS  Google Scholar 

  87. Ahmed N, Williams JF, Weidemann MJ. The human promyelocytic HL60 cell line: a model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate. Biochem Int 1991;23:591–602.

    PubMed  CAS  Google Scholar 

  88. Gamez EJ, Luyengi L, Lee SK, et al. Antioxidant flavonoid glycosides from Daphniphyllum calycinum. J Nat Prod 1998;61:706–708.

    Article  PubMed  CAS  Google Scholar 

  89. Lee D, Park EJ, Cuendet M, et al. Cyclooxygenase-inhibitory and antioxidant constituents of the aerial parts of Antirhea acutata. Bioorg Med Chem Lett 2001;11:1565–1568.

    Article  PubMed  CAS  Google Scholar 

  90. Westenburg HE, Lee KJ, Lee SK, et al. Activity-guided isolation of antioxidative constituents of Cotinus coggygria. J Nat Prod 2000;63:1696–1698.

    Article  PubMed  CAS  Google Scholar 

  91. Jaffe BM. Prostaglandins and cancer: an update. Prostaglandins 1974;6:453–461.

    Article  PubMed  CAS  Google Scholar 

  92. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52:5575–5589.

    PubMed  CAS  Google Scholar 

  93. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997;11: 234–247.

    PubMed  CAS  Google Scholar 

  94. Marnett LJ. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ Health Perspect 1990;88:5–12.

    Article  PubMed  CAS  Google Scholar 

  95. Earashi M, Noguchi M, Kinoshita K, Tanaka M. Effects of eicosanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology 1995;52: 150–155.

    Article  PubMed  CAS  Google Scholar 

  96. Lupulescu A. Prostaglandins, their inhibitors and cancer. Environ Health Perspect 1990;88: 5–12.

    Article  Google Scholar 

  97. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073–1077.

    Article  PubMed  CAS  Google Scholar 

  98. Xie WL, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a target for non-steroidal antiinflammatory drugs. Drug Dev Res 1992;25:245–265.

    Article  Google Scholar 

  99. Smith WL, Garavito RM, De Witt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996;271:33157–33160.

    Article  PubMed  CAS  Google Scholar 

  100. Simmons D, Xie W, Chipman JG, Evett GE. Multiple cyclooxygenases: cloning of a mitogen-inducible form. In Prostaglandin, Leukotrienes, Lipoxins and PAF. Bailey JM, ed. Plenum, New York, 1991; pp. 67–78.

    Google Scholar 

  101. O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156–160.

    Article  PubMed  CAS  Google Scholar 

  102. Dewitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412–1416.

    Article  PubMed  CAS  Google Scholar 

  103. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988;263: 3550–3553.

    PubMed  CAS  Google Scholar 

  104. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304–2312.

    PubMed  CAS  Google Scholar 

  105. Jouzeau JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563–582.

    PubMed  CAS  Google Scholar 

  106. O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89: 4888–4892.

    Article  PubMed  CAS  Google Scholar 

  107. Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isozymes-1 and-2 with NSAIDs. Ann N Y Acad Sci 1994;744:50–57.

    Article  PubMed  CAS  Google Scholar 

  108. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273:21875–21882.

    Article  PubMed  CAS  Google Scholar 

  109. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 1999; 25:65–77.

    PubMed  CAS  Google Scholar 

  110. Jang M, Pezzuto JM. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 1998;134:81–89.

    Article  PubMed  CAS  Google Scholar 

  111. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002; 957:210–229.

    PubMed  CAS  Google Scholar 

  112. Bhat KPL, Kosmeder JW II, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001;3:1041–1064.

    Article  PubMed  CAS  Google Scholar 

  113. Rimando AM, Cuendet M, Desmarchelier C, et al. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002;50:3453–3457.

    Article  PubMed  CAS  Google Scholar 

  114. Waffo-Teguo P, Hawthorne ME, Cuendet M, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer 2001;40:173–179.

    Article  PubMed  CAS  Google Scholar 

  115. Su BN, Cuendet M, Hawthorne ME, et al. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J Nat Prod 2002;65:163–169.

    Article  PubMed  CAS  Google Scholar 

  116. Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 1976;9:77–86.

    Article  CAS  Google Scholar 

  117. Nikolic D, Habibi-Goudarzi S, Corley DG, et al. Evaluation of cyclooxygenase-2 inhibitors using pulsed ultrafiltration mass spectrometry. Anal Chem 2000;72:3853–3859.

    Article  PubMed  CAS  Google Scholar 

  118. Coffino P. Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2001;2: 188–194.

    Article  PubMed  CAS  Google Scholar 

  119. McCann PP, Pegg AE. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 1992; 54:195–215.

    Article  PubMed  CAS  Google Scholar 

  120. Verma AK. Ornithine decarboxylase, a possible target for human cancer prevention. In Cellular and Molecular Targets for Chemoprevention. Steele VE, ed. CRC Press, Boca Raton, 1992; pp.373–389.

    Google Scholar 

  121. Verma AK. Inhibition of tumor promotion by DL-alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase. Basic Life Sci 1990;52:195–204.

    PubMed  CAS  Google Scholar 

  122. Hurta RA. Altered ornithine decarboxylase and S-adenosylmethionine decarboxylase expression and regulation in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein (MAP) kinase kinase. Mol Cell Biochem 2000;215:81–92.

    Article  PubMed  CAS  Google Scholar 

  123. Shantz LM, Pegg AE. Ornithine decarboxylase induction in transformation by H-Ras and RhoA. Cancer Res 1998;58: 2748–2753.

    PubMed  CAS  Google Scholar 

  124. Peralta Soler A, Gilliard G, Megosh L, et al. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 1998;58:1654–1659.

    PubMed  CAS  Google Scholar 

  125. Kubota S, Kiyosawa H, Nomura Y, et al. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst 1997;89: 567–571.

    Article  PubMed  CAS  Google Scholar 

  126. Hardin MS, Mader R, Hurta RA. K-FGF mediated transformation and induction of metastatic potential involves altered ornithine decarboxylase and S-adenosylmethionine decarboxylase expression—role in cellular invasion. Mol Cell Biochem 2002;233:49–56.

    Article  PubMed  CAS  Google Scholar 

  127. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945–951.

    PubMed  CAS  Google Scholar 

  128. Lee SK, Pezzuto JM. Evaluation of the potential of cancer chemopreventive activity mediated by inhibition of 12-O tetradecanoyl phorbol 13-acetate-induced ornithine decarboxylase activity. Arch Pharm Res 1999; 22:559–564.

    PubMed  CAS  Google Scholar 

  129. Gerhäuser C, Mar W, Lee SK, et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1995;1: 260–266.

    Article  PubMed  Google Scholar 

  130. Lee SK, Luyengi L, Gerhäuser C, et al. Inhibitory effect of munetone, an isoflavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity. Cancer Lett 1999; 136: 59–65.

    Article  PubMed  CAS  Google Scholar 

  131. Ito A, Shamon LA, Yu B, et al. Antimutagenic constituents of Casimiroa edulis with potential cancer chemopreventive activity. J Agric Food Chem 1998;46:3509–3516.

    Article  CAS  Google Scholar 

  132. Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review. Antitumour treatment. Cancer Treat Rev 2002;28: 165–180.

    Article  PubMed  CAS  Google Scholar 

  133. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol 2002;3:611–619.

    Article  PubMed  CAS  Google Scholar 

  134. Wolff MS, Toniolo PG, Lee EW, et al. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 1993;85:648–652.

    Article  PubMed  CAS  Google Scholar 

  135. Bradlow HL, Davis DL, Lin G, et al. Effects of pesticides on the ratio of 16α/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 1995;103S: 147–150.

    Article  PubMed  CAS  Google Scholar 

  136. Jensen TK, Toppari J, Keiding N, Skakkebaek NE. Do environmental estrogens contribute to the decline in male reproductive health? Clin Chem 1995;41:1896–1901.

    PubMed  CAS  Google Scholar 

  137. Littlefield BA, Gurpide E, Markiewicz L, et al. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of 5 adrenal steroids. Endocrinology 1990;127:2757–2762.

    PubMed  CAS  Google Scholar 

  138. Holinka CF, Hata H, Kuramoto H, Gurpide E. Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line). Cancer Res 1986;46: 2771–2774.

    PubMed  CAS  Google Scholar 

  139. Albert JL, Sundstrom SA, Lyttle CR. Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res 1990;50: 3306–3310.

    PubMed  CAS  Google Scholar 

  140. Arnold SF, Klotz DM, Collins BM, et al. Synergistic activation of estrogen receptor with combinations of environmental chemicals. Science 1996;272:1489–1492.

    Article  PubMed  CAS  Google Scholar 

  141. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997;94:14138–14143.

    Article  PubMed  CAS  Google Scholar 

  142. Ashby J, Tinwell H, Pennie W, et al. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol 1999;19:39–45.

    Article  PubMed  CAS  Google Scholar 

  143. Bhat KP, Lantvit D, Christov K, et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001;61:7456–7463.

    PubMed  CAS  Google Scholar 

  144. Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 2001;61:6137–6144.

    PubMed  CAS  Google Scholar 

  145. Dmitrieva RI, Doris PA. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function. Exp Biol Med (Maywood) 2002;227:561–569.

    CAS  Google Scholar 

  146. Stenkvist B. Cardenolides and cancer. Anticancer Drugs 2001;12:635–638.

    Article  PubMed  CAS  Google Scholar 

  147. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep 1999;6:493–496.

    PubMed  CAS  Google Scholar 

  148. Brodie A, Njar VCO. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 1998;66:1–10.

    Article  PubMed  CAS  Google Scholar 

  149. Murray R. Role of anti-aromatase agents in postmenopausal advanced breast cancer. Cancer Chemother Pharmacol 2001;48:259–265.

    Article  PubMed  CAS  Google Scholar 

  150. American Cancer Society. Facts and figures, 2002. http://www.cancer.org/downloads/STT/CancerFacts&Figures 2002TM.pdf. Accessed on 11/29/02.

  151. Brodie A, Njar VCO. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999;58:233–255.

    PubMed  Google Scholar 

  152. Recanatini M, Cavalli A, Valenti P. Nonsteroidal aromatase inhibitors: recent advances. Med Res Rev 2002;22:282–304.

    Article  PubMed  CAS  Google Scholar 

  153. Lephart ED. A review of brain aromatase cytochrome P450. Brain Res Rev 1996;22:1–26.

    Article  PubMed  CAS  Google Scholar 

  154. Brodie A, Long B. Aromatase inhibition and inactivation. Clin Cancer Res 2001;7: S4343–S4349.

    Google Scholar 

  155. Brodie A, Long B, Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 1998; 53:S85–S91.

    Article  Google Scholar 

  156. Santen RJ, Martel J, Hoagland M, et al. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblast. Breast Cancer Res Treat 1998;53:S93–S99.

    Article  Google Scholar 

  157. Brodie AMH, Lu Q, Long B. Aromatase and COX-2 expression in human breast cancer. J Steroid Biochem 2001;607:1–7.

    Google Scholar 

  158. Lubet RA, Steele VE, Casebolt TL, et al. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775–2780.

    Article  PubMed  CAS  Google Scholar 

  159. Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 1995;72:72–75.

    PubMed  CAS  Google Scholar 

  160. Kelloff GJ, Lubet RA, Lieberman R, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomark Prev 1998;7:65–78.

    CAS  Google Scholar 

  161. Lonning PE, Kragh LE, Erikstein B, et al. 2001;7: S4423–S4428.

    Google Scholar 

  162. Goss PE, Strasser K. Chemoprevention with aromatase inhibitors-trial strategies. J Steroid Biochem Mol Biol 2001;79:143–149.

    Article  PubMed  CAS  Google Scholar 

  163. Fabian CJ, Kimler BF. Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann NY Acad Sci 2001;952:44–59.

    Article  PubMed  CAS  Google Scholar 

  164. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002;9:2–8.

    PubMed  Google Scholar 

  165. Seralini G, Moslemi S. Aromatase inhibitors: past, present and future. Mol Cell Endocrinol 2001; 178:117–131.

    Article  PubMed  CAS  Google Scholar 

  166. Pouget C, Fagnere C, Basly JP, et al. Synthesis and aromatase inhibitory activity of flavanones. Pharm Res 2002;19:286–291.

    Article  PubMed  CAS  Google Scholar 

  167. Thompson EA Jr, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974;249:5364–5372.

    PubMed  CAS  Google Scholar 

  168. Reed KC, Ohno S. Kinetic properties of human placental aromatase. Application of an assay measuring [3H]2O release from 1β,2β-[3H]-androgens. J Biol Chem 1976;251:1625–1631.

    PubMed  CAS  Google Scholar 

  169. Rabe T, Rabe D, Runnebaum B. New aromatase assay and its application for inhibitory studies of aminoglutethimide on microsomes of human term placenta. J Steroid Biochem 1982;17:305–309.

    Article  PubMed  CAS  Google Scholar 

  170. Stresser DM, Turner SD, McNamara J, et al. Ahigh-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem 2000;284:427–430.

    Article  PubMed  CAS  Google Scholar 

  171. Lee D, Bhat KP, Fong HHS, et al. Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod 2001;64:1286–1293.

    Article  PubMed  CAS  Google Scholar 

  172. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704–1709.

    PubMed  CAS  Google Scholar 

  173. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567–572.

    PubMed  CAS  Google Scholar 

  174. Fearon ER, Burke PJ, Schiffer CA, et al. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 1986;315:15–23.

    PubMed  CAS  Google Scholar 

  175. Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998;4:629–634.

    PubMed  CAS  Google Scholar 

  176. Kelloff GJ, Boone CW, Steele VE, et al. Mechanistic considerations in chemopreventive drug development. J Cell Biochem 1994;20S:1–24.

    Article  CAS  Google Scholar 

  177. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.

    PubMed  CAS  Google Scholar 

  178. Lippman SM, Benner SE, Hong WK. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res 1994;54S:2025–2028.

    Google Scholar 

  179. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216–1222.

    PubMed  CAS  Google Scholar 

  180. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987;70:1233–1244.

    PubMed  CAS  Google Scholar 

  181. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol 1971;55: 283–290.

    PubMed  CAS  Google Scholar 

  182. Yamada M, Kurahashi K. Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 1984;259:3021–3025.

    PubMed  CAS  Google Scholar 

  183. Imaizumi M, Breitman TR. A combination of a T cellderived lymphokine differentiation-inducing activity and a physiologic concentration of retinoic acid induces HL-60 to differentiate to cells with functional chemotactic receptors. Blood 1986;67: 1273–1280.

    PubMed  CAS  Google Scholar 

  184. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 1978;75: 2458–2462.

    Article  PubMed  CAS  Google Scholar 

  185. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells after induction of differentiation by dimethylsulfoxide. J Exp Med 1979; 149: 969–974.

    Article  PubMed  CAS  Google Scholar 

  186. Newburger PE, Speier C, Borregaard N, et al. Development of the superoxide-generating system during differentiation of the HL-60 human promyelocytic leukemia cell line. J Biol Chem 1984;259: 3721–3726.

    Google Scholar 

  187. Suh N, Luyengi L, Fong HHS, et al. Discovery of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model. Anticancer Res 1995;15:233–240.

    PubMed  CAS  Google Scholar 

  188. Luyengi L, Suh N, Fong HHS, et al. A lignan and four terpenoids from Brucea javanica that induce differentiation with cultured HL-60 promyelocytic leukemia cells. Phytochemistry 1996;43:409–412.

    Article  PubMed  CAS  Google Scholar 

  189. Mata-Greenwood E, Cuendet M, Sher D, et al. Brusatolmediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc. Leukemia 2002:16;2275–2284.

    Article  PubMed  CAS  Google Scholar 

  190. Grieco PA, Moher ED, Seya M, et al. A quassinoid (peninsularinone) and a steroid fromCastela peninsularis. Phytochemistry 1994;37:1451–1454.

    Article  Google Scholar 

  191. Moher ED, Grieco PA, Collins JL. (R)-(+)-and (S)-(−)-5-Ethyl-5-methyl-1,3-dioxolane-2,4-dione reagents for the direct preparation of α-hydroxy-α-methylbutyrate esters: assignment of the absolute configuration of the α-acetoxy-α-methylbutyrate ester side chain of quassimarin via total synthesis. J Org Chem 1993;58:3789–3790.

    Article  CAS  Google Scholar 

  192. Moher ED, Reilly M, Grieco PA, et al. Synthetic studies on quassinoids: transformation of (−)-glaucarubolone into (−)-peninsularinone. In vivo antitumor evaluation of (−)-glaucarubolone, (−)-chaparrinone, and (−)-peninsularone. J Org Chem 1998;63:3508–3510.

    Article  CAS  Google Scholar 

  193. Grieco PA, Vander Roest JM, Piñeiro-Nuñez MM, et al. Polyandrol, a C19 quassinoid from Castela polyandra. Phytochemistry 1995;38:1463–1465.

    Article  PubMed  CAS  Google Scholar 

  194. Gu JQ, Gills JJ, Park EJ, et al. Sesquiterpenoids from Tithonia diversifolia with potential cancer chemopreventive activity. J Nat Prod 2002;65:532–536.

    Article  PubMed  CAS  Google Scholar 

  195. Luciferase assay system # TB281, Promega Corporation. Revised 5/2000.

    Google Scholar 

  196. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241–246.

    Article  PubMed  CAS  Google Scholar 

  197. Mehta RG. Experimental basis for breast cancer. Eur J Cancer 2000;36:1275–1282.

    Article  PubMed  CAS  Google Scholar 

  198. Moon RC, Mehta RG, Rao KVN. Retinoids in experimental animals. In The Retinoids: Biology, Chemistry and Medicine. Sporn MB, Roberts AB, Goodman DS, eds. New York: Raven Press, 1997: pp. 573–595.

    Google Scholar 

  199. Hsieh TC, Wu JM. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 2000;20: 225–228.

    PubMed  CAS  Google Scholar 

  200. Zhang Y, Kensler TW, Cho CG, et al. Anticarcinogenic activity of sulforaphane and structurally related isothiocyanates. Proc Natl Acad Sci USA 1994;91:3147–3150.

    Article  PubMed  CAS  Google Scholar 

  201. Planck M. The Philosophy of Physics. New York: WW. Norton & Company, Inc., 1936.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, Purdue University, West Lafayette, IN

    John M. Pezzuto PhD

  2. Ventana Medical Systems Inc., Tucson, AZ

    Jerome W. Kosmeder II PhD

  3. Developmental Therapeutics Program, Tumor Hypoxia Laboratory, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD

    Eun-Jung Park PhD

  4. College of Pharmacy, Ewha Womans University, Seoul, Korea

    Sang Kook Lee PhD

  5. Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL

    Muriel Cuendet PhD, Hye-Sung Park, YingMeei Tan PhD & Daniel D. Lantvit

  6. Cancer Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Joell Gills PhD

  7. Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

    Krishna Bhat PhD

  8. Department of Biomedical Engineering, Northwestern University, Evanston, IL

    Simonida Grubjesic PhD

  9. Division of Pediatric Research, Northwestern University, Evanston, IL

    Eugenia Mata-Greenwood PhD

  10. Medical School, The University of Texas Health Science Center at Houston, Houston, TX

    Rong Yu PhD

  11. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, OH

    A. Douglas Kinghorn PhD, DSc

Authors
  1. John M. Pezzuto PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerome W. Kosmeder II PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eun-Jung Park PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sang Kook Lee PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muriel Cuendet PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joell Gills PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Krishna Bhat PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Simonida Grubjesic PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hye-Sung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eugenia Mata-Greenwood PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. YingMeei Tan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rong Yu PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Daniel D. Lantvit
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Douglas Kinghorn PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Pezzuto, J.M. et al. (2005). Characterization of Natural Product Chemopreventive Agents. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation